Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
NCT04832399
·
clinicaltrials.gov ↗
COMPLETED
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
DRUG:
Natalizumab
Sponsor
Biogen